Final Results from REPRISE III: Long-Term Stroke Risk after TAVR for Severe Aortic Stenosis – DocWire News

A study presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2021 Annual Meeting reported the final five-year results from the REPRISE III randomized trial, which assessed the Lotus Valve transcatheter aortic valve replacement (TAVR) system…

Click here to view the original article.